Asia Pacific Cell And Gene Therapy Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Cell And Gene Therapy CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the cell and gene therapy cdmo market
Asia Pacific cell and gene therapy cdmo market highlights
- The Asia Pacific cell and gene therapy cdmo market generated a revenue of USD 751.2 million in 2024.
- The market is expected to grow at a CAGR of 23.8% from 2025 to 2033.
- In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
- Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 751.2 million |
| Market revenue in 2033 | USD 4,989.5 million |
| Growth rate | 23.8% (CAGR from 2025 to 2033) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 17.4% of the global cell and gene therapy cdmo market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,989.5 million by 2033.
Asia Pacific held the revenue share of 37.55% in the global market in 2023. This growth can be attributed to various factors, such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In recent years, countries such as Singapore, China, and India are considered to be major players in the pharmaceutical industry due to their expanding manufacturing capabilities. In addition, the manufacturing of pharmaceutical products has been outsourced to Asian countries in the past decade, including India & China.
Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries, such as India.
No credit card required*
Publish Date: Sep 08, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Samsung Electronics Co Ltd | View profile | 124,804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | www.samsung.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| OmniAb Inc | View profile | 106 | 5980 Horton Street, Suite 600, Emeryville, CA, United States, 94608 | www.omniab.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| AGC Inc | View profile | 61,671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | www.agc.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | www.rentschler-biopharma.com |
Asia Pacific Cell And Gene Therapy CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.
Pre-Clinical was the largest segment with a revenue share of 77.5% in 2024.
Horizon Databook has segmented the Asia Pacific cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific held the revenue share of 37.55% in the global market in 2023. This growth can be attributed to various factors, such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In recent years, countries such as Singapore, China, and India are considered to be major players in the pharmaceutical industry due to their expanding manufacturing capabilities. In addition, the manufacturing of pharmaceutical products has been outsourced to Asian countries in the past decade, including India & China.
Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries, such as India.
- Asia Pacific Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
- Pre-clinical
- Clinical
- Asia Pacific Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Rare Diseases
- Others
- Oncology
- Infectious Diseases
- Neurological disorders
- Asia Pacific Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- Gene Therapy
- Gene-Modified Cell Therapy
- Cell Therapy
Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy CDMO Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)
Asia Pacific cell and gene therapy cdmo market statistics, by phase, 2021-2033 (US$M)
